Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIIb Study for Relapsed/Refractory Pediatric/Young Adult Acute Lymphoblastic Leukemia Patients to be Treated With CTL019

X
Trial Profile

Phase IIIb Study for Relapsed/Refractory Pediatric/Young Adult Acute Lymphoblastic Leukemia Patients to be Treated With CTL019

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; Cytarabine (Primary) ; Etoposide (Primary) ; Fludarabine (Primary) ; Siltuximab (Primary) ; Tisagenlecleucel (Primary) ; Tocilizumab (Primary)
  • Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions
  • Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
  • Most Recent Events

    • 12 Dec 2023 Results of analysis assessing impact of CAR persistence and B cell aplasia on duration of remission based on long term follow up data from pivotal phase II studies in patents with r/r ALL (ELIANA, ENSIGN, NCT03123939, NCT01626495), r/r DLBCL (JULIET), and r/r FL (ELARA), along with the long term follow up study (NCT02445222) presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 01 Jun 2022 Results assessing Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia from three trials (ELIANA [NCT02435849], ENSIGN [NCT02228096] and B2001X [NCT03123939) published in the Leukemia
    • 11 Nov 2020 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top